Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB006 in advanced malignancies
NCT05253105Phase 1Withdrawn
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of JS006 in solid tumor (advanced stage) and lymphoma, sponsored by Shanghai Junshi Biosciences Co., Ltd. Planned start Mar 2022; status: withdrawn.
02
Drugs
JS006
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05253105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253105.